Larimar Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its proprietary cell-penetrating peptide technology platform. This platform enables intracellular delivery of missing proteins to address devastating conditions with limited or no available therapies. The company's lead product candidate, nomlabofusp, is in Phase 2 clinical trials, including ongoing long-term open-label and open-label extension studies, for Friedreich’s ataxia, a rare, progressive genetic disease caused by frataxin deficiency. Nomlabofusp aims to restore frataxin protein levels, with data showing increases in skin frataxin concentrations and directional improvements in clinical measures. Larimar Therapeutics Inc. is advancing nomlabofusp toward potential regulatory submissions and also plans to apply its platform to other rare diseases involving intracellular protein deficiencies. Headquartered in Bala Cynwyd, Pennsylvania, the company plays a key role in the rare disease biotechnology sector by targeting unmet needs in mitochondrial and genetic disorders.